New Delhi, Aug. 12 -- Zydus Lifesciences beat Street estimates in the June quarter on the back of steady India growth, a stronger US portfolio, and surging international sales. This sets the stage for its biosimilars push in the world's largest pharmaceuticals market following a $125 million manufacturing acquisition.

The Ahmedabad-based drugmaker reported a revenue growth of 6% year-on-year (y-o-y) to Rs.6,573 crore, and a net profit of Rs.1,466 crore, up 3%. Its Ebitda was Rs.2,088 crore, with the margin at 31.8%. A Bloomberg poll had pegged its revenues at Rs.6,477 crore and profit after tax at Rs.1,332 crore.

In the June quarter, Zydus's India business clocked an 8% y-o-y growth, driven by chronic therapies and innovation-led portfo...